Accelerate Diagnostics announced that the new IVD configuration of its Accelerate PhenoTest BC kit has been CE marked and is ready for use in Europe.

The new configuration, which launched in the United States in July, provides fast antimicrobial susceptibility testing (AST) results in approximately 7 hours direct from positive blood cultures and is designed to run on the Accelerate Pheno system as a flexible solution for laboratories that already have a rapid identification system. This is an important new option for the Company's existing Accelerate PhenoTest BC kit, which already had an ID/AST configuration that is a fully integrated solution for labs needing both fast identification and fast AST.

The Accelerate Pheno system has been shown to deliver improvements in clinical outcomes including time to results, time to optimal therapy, duration of therapy and hospital length of stay.

“This product expansion provides fast phenotypic, MIC-based AST results and unique flexible workflow options to accommodate the different clinical and laboratories settings across Europe,” said Cherif Bousselham, senior vice president, head of sales, EMEA, for Accelerate Diagnostics.